Sharmilan Thanendrarajan MD

PubMed

• Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical Trials.
  Samer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, Sharmilan Thanendrarajan, Eric R Siegel
  JAMA Oncology. 2025-06-05
• Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma.
  Fumou Sun, Yan Cheng, Catherine Ma, Hongwei Xu, Clyde Bailey
  Cancer Biomarkers. 2025-06-01
• Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma.
  Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D Shaughnessy Jr, Fenghuang Zhan
  Blood Advances. 2025-05-13

Journal Articles

• Mesenchymal Stem Cells Gene Signature in High‐Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2‐Expressing Small Adipocytes  
  Bart Barlogie, Sharmilan Thanendrarajan, Carolina Schinke, British Journal of Haematology

Abstracts/Posters

• The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma
  Sharmilan Thanendrarajan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells
  Sharmilan Thanendrarajan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells
  Sharmilan Thanendrarajan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
  Sharmilan Thanendrarajan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Mye...
  Sharmilan Thanendrarajan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Mutational Landscape of Primary Plasma Cell Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all